• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

个性化卵巢刺激在辅助生殖技术中的应用:从炒作到为患者增值的研究设计考虑因素。

Personalized ovarian stimulation for assisted reproductive technology: study design considerations to move from hype to added value for patients.

机构信息

Monash University, Clayton, Victoria, Australia.

University of Amsterdam, Amsterdam, the Netherlands.

出版信息

Fertil Steril. 2018 Jun;109(6):968-979. doi: 10.1016/j.fertnstert.2018.04.037.

DOI:10.1016/j.fertnstert.2018.04.037
PMID:29935655
Abstract

Although most medical treatments are designed for the average patient with a one-size-fits-all-approach, they may not benefit all. Better understanding of the function of genes, proteins, and metabolite, and of personal and environmental factors has led to a call for personalized medicine. Personalized reproductive medicine is still in its infancy, without clear guidance on treatment aspects that could be personalized and on trial design to evaluate personalized treatment effect and benefit-harm balance. While the rationale for a personalized approach often relies on retrospective analyses of large observational studies or real-world data, solid evidence of superiority of a personalized approach will come from randomized trials comparing outcomes and safety between a personalized and one-size-fits-all strategy. A more efficient, targeted randomized trial design may recruit only patients or couples for which the personalized approach would differ from the previous, standard approach. Multiple monocenter studies using the same study protocol (allowing future meta-analysis) might reduce the major center effect associated with multicenter studies. In certain cases, single-arm observational studies can generate the necessary evidence for a personalized approach. This review describes each of the main segments of patient care in assisted reproductive technologies treatment, addressing which aspects could be personalized, emphasizing current evidence and relevant study design.

摘要

虽然大多数医疗方法都是针对具有普遍适用性的一般患者设计的,但它们可能并不适用于所有人。对基因、蛋白质和代谢物的功能以及个人和环境因素的更好理解,导致了人们呼吁采用个性化医疗。个性化生殖医学仍处于起步阶段,对于可以个性化的治疗方面以及评估个性化治疗效果和利弊平衡的试验设计,尚无明确的指导。虽然个性化方法的基本原理通常依赖于对大型观察性研究或真实世界数据的回顾性分析,但从比较个性化方法和一刀切策略的结果和安全性的随机试验中,才能获得个性化方法具有优越性的可靠证据。一种更有效、有针对性的随机试验设计可能只招募那些个性化方法与之前的标准方法不同的患者或夫妇。使用相同研究方案的多项单中心研究(允许未来进行荟萃分析)可能会减少与多中心研究相关的主要中心效应。在某些情况下,单臂观察性研究可以为个性化方法提供必要的证据。本综述描述了辅助生殖技术治疗中患者护理的主要环节,探讨了哪些方面可以实现个性化,并强调了当前的证据和相关研究设计。

相似文献

1
Personalized ovarian stimulation for assisted reproductive technology: study design considerations to move from hype to added value for patients.个性化卵巢刺激在辅助生殖技术中的应用:从炒作到为患者增值的研究设计考虑因素。
Fertil Steril. 2018 Jun;109(6):968-979. doi: 10.1016/j.fertnstert.2018.04.037.
2
Introduction: Personalized medicine: what is it and what are the challenges?介绍:个性化医学:它是什么,以及面临哪些挑战?
Fertil Steril. 2018 Jun;109(6):944-945. doi: 10.1016/j.fertnstert.2018.04.027.
3
Personalized medicine: motivation, challenges, and progress.个性化医学:动机、挑战与进展。
Fertil Steril. 2018 Jun;109(6):952-963. doi: 10.1016/j.fertnstert.2018.05.006.
4
Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.重组人促卵泡激素α/重组人促黄体生成素α在辅助生殖技术中的疗效与安全性:一项针对卵巢反应不良患者的随机对照试验。
Hum Reprod. 2017 Mar 1;32(3):544-555. doi: 10.1093/humrep/dew360.
5
e-Therapy to reduce emotional distress in women undergoing assisted reproductive technology (ART): a feasibility randomized controlled trial.电子治疗减轻接受辅助生殖技术(ART)治疗的女性的情绪困扰:一项可行性随机对照试验。
Hum Reprod. 2016 May;31(5):1046-57. doi: 10.1093/humrep/dew040. Epub 2016 Mar 10.
6
Melatonin supplementation during controlled ovarian stimulation for women undergoing assisted reproductive technology: systematic review and meta-analysis of randomized controlled trials.褪黑素补充剂在接受辅助生殖技术的妇女控制性卵巢刺激中的应用:随机对照试验的系统评价和荟萃分析。
Fertil Steril. 2014 Jan;101(1):154-161.e4. doi: 10.1016/j.fertnstert.2013.09.036. Epub 2013 Oct 29.
7
Personalized reproductive medicine: regulatory considerations.个性化生殖医学:监管考虑因素。
Fertil Steril. 2018 Jun;109(6):964-967. doi: 10.1016/j.fertnstert.2018.03.027.
8
The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis.应用重组促黄体生成素治疗高龄不孕患者行辅助生殖技术:系统评价和荟萃分析。
Fertil Steril. 2012 May;97(5):1108-14.e1. doi: 10.1016/j.fertnstert.2012.01.130. Epub 2012 Feb 24.
9
Pregnancy outcomes after assisted human reproduction.人类辅助生殖后的妊娠结局
J Obstet Gynaecol Can. 2014 Jan;36(1):64-83. doi: 10.1016/S1701-2163(15)30685-X.
10
Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.1050名女性在一个辅助生殖技术周期(包括所有后续冻融周期)后的累积活产率:一项比较促性腺激素释放激素拮抗剂和促性腺激素释放激素激动剂方案的随机对照试验的次要结果。
Hum Reprod. 2017 Mar 1;32(3):556-567. doi: 10.1093/humrep/dew358.

引用本文的文献

1
Management of LH/FSH deficiency among assisted reproduction specialists in Spain: a Delphi consensus.西班牙辅助生殖专家对促黄体生成素/促卵泡生成素缺乏症的管理:德尔菲共识
Front Endocrinol (Lausanne). 2025 Aug 5;16:1498062. doi: 10.3389/fendo.2025.1498062. eCollection 2025.
2
Real-world use of an artificial intelligence-powered clinical decision support tool for ovarian stimulation.人工智能驱动的卵巢刺激临床决策支持工具的实际应用。
F S Rep. 2025 Jan 28;6(2):140-146. doi: 10.1016/j.xfre.2025.01.015. eCollection 2025 Jun.
3
Assessing the uptake of infertility core outcome set in IVF randomized controlled trials.
评估体外受精随机对照试验中不孕症核心结局集的采用情况。
Hum Reprod. 2025 Jan 1;40(1):85-95. doi: 10.1093/humrep/deae255.
4
From patient classification to optimized treatment in ART: the AMPLITUDE Delphi consensus.从患者分类到抗逆转录病毒治疗的优化:AMPLITUDE德尔菲共识。
Front Reprod Health. 2024 Sep 27;6:1467322. doi: 10.3389/frph.2024.1467322. eCollection 2024.
5
Harnessing Artificial Intelligence to Predict Ovarian Stimulation Outcomes in In Vitro Fertilization: Scoping Review.利用人工智能预测体外受精中卵巢刺激的结果:范围综述。
J Med Internet Res. 2024 Jul 5;26:e53396. doi: 10.2196/53396.
6
Fine-tuning the dose of recombinant human follicle-stimulating hormone alfa to individualize treatment in ovulation induction and ovarian stimulation cycles: a real-world database analysis.调整重组人促卵泡激素阿尔法的剂量以实现个体化治疗:排卵诱导和卵巢刺激周期的真实世界数据库分析。
Front Endocrinol (Lausanne). 2023 Sep 1;14:1195632. doi: 10.3389/fendo.2023.1195632. eCollection 2023.
7
An Online Tool Using Basal or Activated Ovarian Reserve Markers to Predict the Number of Oocytes Retrieved Following Controlled Ovarian Stimulation: A Prospective Observational Cohort Study.一种使用基础或激活卵巢储备标志物预测控制性卵巢刺激后可获取卵母细胞数量的在线工具:一项前瞻性观察队列研究。
Front Endocrinol (Lausanne). 2022 May 27;13:881983. doi: 10.3389/fendo.2022.881983. eCollection 2022.
8
A comparative, observational study evaluating dosing characteristics and ovarian response using the recombinant human follicle-stimulating hormone pen injector with small-dose dial in assisted reproductive technologies treatment in Asia: IMPROVE study.一项比较性、观察性研究,评估了在亚洲使用重组人卵泡刺激素笔式注射器和小剂量拨盘辅助生殖技术治疗中的剂量特征和卵巢反应:改善研究。
Reprod Biol Endocrinol. 2022 Jan 17;20(1):15. doi: 10.1186/s12958-021-00882-2.
9
Self-Monitoring of Urinary Hormones in Combination with Telemedicine - a Timely Review and Opinion Piece in Medically Assisted Reproduction.自我监测尿液中的激素水平并结合远程医疗——医学辅助生殖中的及时综述和观点文章。
Reprod Sci. 2022 Nov;29(11):3147-3160. doi: 10.1007/s43032-021-00754-5. Epub 2021 Nov 15.
10
Interplay Between mTOR and Hippo Signaling in the Ovary: Clinical Choice Guidance Between Different Gonadotropin Preparations for Better IVF.mTOR 与 Hippo 信号通路在卵巢中的相互作用:不同促性腺激素制剂在 IVF 中更好选择的临床指导
Front Endocrinol (Lausanne). 2021 Jul 21;12:702446. doi: 10.3389/fendo.2021.702446. eCollection 2021.